Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

TOVX holding history

Theriva Biologics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TOVX overviewAll 13F holders of TOVXFull Q2 2026 holdings

Shares (Q2 2026)
61,053
Value
$15.3K
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of TOVX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202661,053$15.3K<0.1%−164,571−72.9%ReducedHolders
Q1 2026225,624$44.2K<0.1%+34,214+17.9%AddedHolders
Q4 2025191,410$40.2K<0.1%+168,497+735.4%AddedHolders
Q3 202522,913$9.28K<0.1%+22,912+2,291,200.0%AddedHolders
Q2 20251$00.0%−7,850−100.0%ReducedHolders
Q1 20257,851$8.64K<0.1%−8,555−52.1%ReducedHolders
Q4 202416,406$28.7K<0.1%−1,445−8.1%ReducedHolders
Q3 202417,851$24.6K<0.1%+17,848+594,933.3%AddedHolders
Q2 20243$1<0.1%00.0%UnchangedHolders
Q1 20243$1<0.1%00.0%UnchangedHolders
Q4 20233$1<0.1%+3NewHolders
Q3 20230$00.0%−5,933−100.0%Sold outHolders
Q2 20235,933$5.93K<0.1%+5,933NewHolders
Q1 20230$00.0%−5,015−100.0%Sold outHolders
Q4 20225,015$2.31K<0.1%−1,751−25.9%ReducedHolders
Q3 20226,766$7.00K<0.1%+6,357+1,554.7%AddedConverted for a 1-for-10 splitHolders
Q2 20224,089$1.00K<0.1%−75,762−94.9%ReducedHolders
Q1 202279,851$23.0K<0.1%−17,527−18.0%ReducedHolders
Q4 202197,378$26.0K<0.1%+44,867+85.4%AddedHolders
Q3 202152,511$24.0K<0.1%+52,452+88,901.7%AddedHolders
Q2 202159$00.0%−576,868−100.0%ReducedHolders
Q1 2021576,927$393.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.